12,000 diseases lack treatments. One doctor thinks generics could yield cures
SAN FRANCISCO — About a decade ago, David Fajgenbaum thought his life was over. He…
Category: Pharmaceuticals
Amid booming demand, Novo to hold back some doses of obesity drug Wegovy for new U.S. patients
Novo Nordisk, the maker of the wildly popular obesity drug Wegovy, said Thursday it would…
STAT+: New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced…
STAT+: CAR-T research is flourishing but is hampered by outdated precautions, experts say
Twenty years ago, CAR-T cell therapy was not quite “believed in,” said Michel Sadelain, director…
STAT+: What the Covid-19 pandemic can teach us about drug patents
Inventing treatments and vaccines is only part of the battle in an epidemic and pandemic,…
STAT+: Disagreements and digs upend an otherwise bipartisan hearing on PBM reform
WASHINGTON — The first Senate health committee markup under Chairman Bernie Sanders (I-Vt.) and ranking…
STAT+: A battle between Gilead and the U.S. government over patents on HIV prevention pills goes to trial
After years of sparring, the federal government and Gilead Sciences will square off in a…
Travere Therapeutics drug, approved for one rare and deadly kidney disease, fails in study of another
SAN DIEGO — Travere Therapeutics, a biotech focused on treating rare diseases, on Monday announced…
STAT+: Most of Canada’s public research universities get bad grades for ensuring access to drugs they discover
Despite significant public funding, most of the 15 largest public research universities in Canada failed…
.jpg)
STAT+: Beyond Wegovy and Ozempic: Biotechs vie for piece of red-hot weight loss market with novel strategies
This is part of a series about new obesity drugs that are transforming patients’ lives,…
STAT+: Once bullish on digital health, Orexo hits a wall on reimbursement
After several quarters of promising to deliver concrete progress on key digital therapeutics projects, Swedish…
STAT+: Covid-19 burnished pharma’s reputation among patient groups, but access to medicines is now an issue
In the wake of the Covid-19 pandemic, the pharmaceutical industry enjoyed something of an afterglow,…
Listen: Explaining the E.U.’s pharma overhaul, Lilly’s booming business, & a long-awaited drug approval
Is a specter haunting Europe? Will Eli Lilly usurp Johnson & Johnson? And what does…
STAT+: Pharma executives flood Bill Cassidy with campaign cash
WASHINGTON — Sen. Bill Cassidy’s new perch as the top Republican on the Senate health…
STAT+: EU releases proposed pharma overhaul, cutting period of market exclusivity
LONDON — The European Commission on Wednesday unveiled a long-awaited proposed update for how the…
.jpg)
Opinion: STAT+: At-home clinical trials are the future
In the early days of the Covid-19 pandemic, much of the clinical trials industry came…
STAT+: Sens. Bernie Sanders, Bill Cassidy reach deal on PBM, generic reform
WASHINGTON — Senate health committee leaders Bernie Sanders and Bill Cassidy on Tuesday announced an agreement…
With little FDA oversight, melatonin supplements vary widely in actual dosage, study finds
WASHINGTON — Consumers turning to melatonin gummies to get some help falling asleep might be…
STAT+: ‘A tug of war’: Europe braces for new legislation with far-reaching impacts on pharma and patients
After more than two years of planning, the European Commission on Wednesday will release long-awaited…
Supreme Court maintains access to abortion pill mifepristone, at least for now
WASHINGTON — The U.S. Supreme Court on Friday ruled 7-2 that a commonly used abortion…
STAT+: Pharmalittle: Lilly expects Medicare to back down on Alzheimer’s drug coverage; key senators change insulin cap proposal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Narcan manufacturer aims to price over-the-counter kit under $50
The manufacturer of Narcan, the overdose reversal medication that received over-the-counter status last month, says…
STAT+: Powerful Senate duo drops a bipartisan PBM reform plan
WASHINGTON — The chair and ranking Republican on the Senate Finance Committee on Thursday unveiled…
STAT+: Stock drama, cancer vaccine success, and new science – highlights from AACR
ORLANDO, Fla. – There was some drama at the American Association for Cancer Research annual…
FDA’s new plan to study opioids’ effectiveness faces resistance
The Food and Drug Administration’s latest plan to study whether opioids are effective as a…
Opinion: The window is closing to stop deadly drug-resistant fungi like Candida auris
Just one week after the season finale of the HBO show “The Last of Us,”…
STAT+: Mark Cuban’s drug company creates a pharmacy network to challenge PBMs
In its latest bid to upend the pharmaceutical supply chain, the Mark Cuban Cost Plus…
STAT+: GSK to buy Bellus Health for $2 billion, gaining chronic cough drug
LONDON — GSK said Tuesday it would purchase Bellus Health for $2 billion, adding a…
Q&A: What does it mean when a clinical trial is delayed? More than you think
Frank David was just starting an independent research program on cell signaling in cancer and…
Opinion: I’m a biopharma supply chain specialist — and even I can’t find the Adderall I’m prescribed
For 10 years, I have depended on Adderall to help me function. But in February,…
STAT+: ‘Style over substance?’ Express Scripts launches new pricing plan amid rising scrutiny of PBMs
Amid increasing scrutiny of pharmacy benefit managers, Express Scripts is launching a new pricing plan…
STAT+: Senate hashing out policy details on generics, PBMs, insulin
WASHINGTON — Senators are slightly delaying their latest legislative push on health care, but as they…
STAT+: Sanders plans to haul insulin executives to testify in Senate
WASHINGTON — Sen. Bernie Sanders plans to call the chief executives of the country’s largest…
6 burning questions about how the FDA will handle conflicting abortion pill decisions
A dueling pair of federal court decisions has thrown the fate of the abortion pill…
Listen: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers
Is Illumina the Disney of biotech? Does the Texas two-step work after all? And can…
STAT+: FDA withdraws approval of controversial drug to prevent preterm births
After a years-long controversy, the U.S. Food and Drug Administration ordered the immediate withdrawal of a…
STAT+: Cancer drug shortages have plagued the U.S. for years. Can they be fixed?
Roughly two million Americans are expected to receive a cancer diagnosis this year. Some members…
STAT+: ‘True disruption’: Mark Cuban’s company will sell brand-name diabetes medicines from Janssen
For the first time, Mark Cuban’s Cost Plus Drug Company is selling medicines made by…
STAT+: Pharmalittle: FDA slams company recalling eye drops over manufacturing issues; U.S. funds massive Alzheimer’s research database
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: The biotech scorecard for the second quarter: 24 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second…
STAT+: European Union drug pricing proposal for the pandemic treaty generates pushback
Amid treaty talks to create equitable access to medical products during pandemics, the European Union…
STAT+: Inflation caused a sizable drop in net drug prices in late 2022, analysis finds
Amid ongoing debate over the cost of prescription medicines, a new analysis finds that brand-name…
STAT+: FDA report details problems at Global Pharma plant involved in eye drop recall
Global Pharma Healthcare, whose eye drops have been linked to dozens of serious reactions, failed…
Opinion: STAT+: 3 keys to successful biopharma-academia drug development collaborations
Academia can be an excellent source of novel drug targets and new technologies that can…
STAT+: Drug middlemen switch tactics, but the outcome is the same: high prices
WASHINGTON — Prescription drug middlemen are shifting away from rebates that have been blamed in…
Listen: Biotech’s monkey shortage, the broken generics market, & conference cancel culture
What happened to the market for monkeys? Are some drugs too cheap? And why are…
Pressure is building on pharma and biotech companies to take climate action
As the health impacts of climate change become harder to ignore, biotechnology and pharmaceutical companies…
STAT+: Viking Therapeutics releases early but promising weight loss data on new GLP-1 drug
Viking Therapeutics, a small biotechnology company, said Tuesday that its experimental medicine led patients to…
A half century after Prozac, a new generation of depression drugs is bringing hope to a long-stagnant field
This article is excerpted from the latest STAT Report: Treating Depression: a new era of…
STAT+: Ohio attorney general accuses pharmacy benefit managers of drug price fixing
The Ohio attorney general filed a lawsuit on Monday accusing three large pharmacy benefit managers…